Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PRKCG | P05129 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277945 | 0.92 | KMT2A (0.47) | TSHRALDH1A1HPGDKMT2ACYP3A4 | |
| SCHEMBL3273959 | 0.90 | ROCK1 (0.44) | TSHRKMT2ACYP3A4ROCK1GSK3B | |
| SCHEMBL3273858 | 0.90 | GSK3B (0.45) | TSHRKMT2ACYP3A4ROCK1GSK3B | |
| SCHEMBL3278158 | 0.89 | TSHR (0.43) | TSHRPDE2A | |
| SCHEMBL3273618 | 0.89 | ROCK1 (0.45) | TSHRKMT2ACYP3A4ROCK1GSK3B | |
| SCHEMBL3274977 | 0.88 | TSHR (0.42) | TSHRALDH1A1HPGDKMT2ACYP3A4 | |
| SCHEMBL3274899 | 0.88 | TSHR (0.42) | TSHRALDH1A1KMT2ACYP3A4ROCK1 | |
| SCHEMBL3277952 | 0.88 | KCNMA1 (0.46) | TSHRALDH1A1KMT2ACYP3A4ROCK1 | |
| SCHEMBL3144849 | 0.88 | ROCK1 (0.42) | TSHRALDH1A1KMT2ACYP3A4ROCK1 | |
| SCHEMBL3277970 | 0.86 | PDE2A (0.46) | TSHRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | claimed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | claimed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | claimed |
| EP-2148866-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | claimed |
| WO-2008155669-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | claimed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | claimed |
| US-8592436-B2 | Arylamide pyrimidone derivatives | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2148866-B1 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| EP-2148866-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008155669-A2 | ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992620-A1 | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087460-A1 | ARYLAMIDE PYRIMIDONE DERIVATIVES | DHFR, XDH, HPRT1 | TSHR 479/4885ALDH1A1 134/4885HPGD 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.